Competitive strengths in preclinical translational medicine
Our competitive strengths in preclinical translational medicine and global commercial pharmaceutical development include expertise in the following service areas: GAP and Risk Analysis of preclinical in vitro/in vivo assessment of MOA, safety, identifying and justifying a safe starting dose and dose escalation scheme, pharmacology, pharmacodynamics, trial design and endpoints and identifying and optimizing safe and effective dose levels, prioritizing target patient populations, competitive analysis, drug testing in relevant animal models, PK assay and testing assessments, regulatory meeting preparation and guidance.
We can identify and solve GAPs and risks in the Sponsor’s development programs and help them to achieve their development objectives cost effectively.
Global commercial IND/Phase I-III and NDA/BLA development in the US, China, Europe, Japan, and ROW.
Due diligence, GAP and risk assessments; solutions/mitigation.